Long-Time Survival of a Patient with Metastatic Pancreatic Cancer: A Case Report

Željko Soldić    Daniela Žitnjak    Ante Bolanča    Zvonko Kusić
Department of Oncology and Nuclear Medicine, Clinical Hospital Center Sisters of Mercy, Zagreb, Croatia

Key Words
Cancer · Pancreas · Liver metastases · Cisplatin

Abstract
Pancreatic cancer is a malignant neoplasm of the pancreas. It does not cause any symptoms in the early stage, and later symptoms are nonspecific, thus the disease is usually diagnosed when already advanced. In 2008, pancreatic cancer ranked eighth on the list of the 10 most common cancers among men in Croatia and tenth on the list of the most common cancers among Croatian women. Pancreatic cancer has a poor prognosis, with a survival time of only 6–8 months for metastatic disease. Gemcitabine is the standard chemotherapeutic option. Other chemotherapeutic agents include 5-fluorouracil and leucovorin. In this paper, we present a case of a patient diagnosed with locally advanced and metastatic pancreatic cancer, who is still alive and currently receives his fourth line of chemotherapy 5 years after the diagnosis. Following disease progression on gemcitabine chemotherapy, he was treated with chemoradiotherapy which, however, had no effect. We then applied cisplatin monochemotherapy which offered excellent disease control, was well tolerated by the patient and, although somewhat obsolete in this form, showed to be a valuable chemotherapeutic option.

Introduction
Pancreatic cancer is a malignant neoplasm of the pancreas. Endocrine pancreatic tumors account for only about 1% of all cases. In contrast, exocrine tumors are far more common, with 95% of them being adenocarcinomas while the remaining 5% include adenosquamous carcinomas, signet ring cell carcinomas, hepatoid carcinomas, colloid carcinomas, undifferentiated carcinomas, and undifferentiated carcinomas with osteoclast-like giant cells [1]. Because pancreatic cancer does not cause any symptoms in
the early stage and the later symptoms are nonspecific and vary, the disease is usually
diagnosed when already advanced and, thus, the survival is poor. Each year,
approximately 32,000 patients are diagnosed with pancreatic cancer in the United States,
and approximately 31,000 patients die from it each year, making pancreatic cancer the
fourth leading cause of cancer-related death [2]. In 2008, with an incidence rate of
374/100,000 and a mortality rate of 363/100,000, pancreatic cancer ranked eighth on
the list of the 10 most common cancers among men in Croatia [3]. The incidence and
mortality rates of pancreatic cancer among Croatian women were somewhat lower, with
349 and 316 per 100,000, respectively, making it number 10 on the list of the most
common cancers [3].

According to the analysis of 684 patients treated for pancreatic cancer in the Memorial
Sloan-Kettering Cancer Center, the median survival time for patients with pancreatic
ductal carcinoma who underwent resection was 14.3 months, but only 4.9 months for
unresectable patients [4]. Gemcitabine is the standard chemotherapy option [5].
Capecitabine has been shown to provide long-term survival (approx. 4 years) in 2 patients
with metastatic pancreatic cancer after gemcitabine treatment failure, possibly due to its
higher activity of thymidine phosphorylase, an enzyme that activates 5-fluorouracil
(5-FU) in tumor tissues, and thus its higher thymidine phosphorylase/dihydropyrimidine
dehydrogenase ratio which could predict survival benefit with 5-FU-based agents [6].

Case Report

A 42-year-old male with jaundice, weight loss, nocturnal upper right quadrant abdominal pain,
diarrhea and postprandial epigastric pain was hospitalized after ultrasonically suspected infiltration in
the head of the pancreas. An abdominal CT scan showed an expansive lesion retropancreatically,
between the pancreas and inferior vena cava and below the portal vein, measuring 41 × 25 mm, with
enlarged para-aortic and interaortocaval lymph nodes, a dilated intra- and extrahepatic biliary tree
and stenosis of the common bile duct. An endoscopic retrograde cholangiopancreatography was
performed, and the patient was referred to an abdominal surgeon. During explorative laparotomy, the
tumor was found to be inoperable because of local vascular infiltration and liver metastases.
Pathohistological diagnosis confirmed the clinical diagnosis.

One month later, chemotherapy with gemcitabine was started. After 6 cycles of chemotherapy (i.e.
22 applications), a CT scan showed no liver metastases; however, the tumor in the head of the pancreas
was still visible and unchanged in size. The patient was again referred to a surgeon who declined the
possibility of an operative procedure. Therefore, chemoradiotherapy was started during which the
patient received the planned dose of 41.4 Gy (23 × 1.8 Gy) simultaneously with monthly intravenous
5-FU (5-day chemotherapy, 6 cycles). CT monitoring of the tumor response to chemoradiotherapy
showed a relapse of the liver metastases, with no change in the size of the primary tumor or enlarged
abdominal lymph nodes. Thus, a third line of chemotherapy with cisplatin monotherapy was started.
After 5 cycles, a CT scan revealed stationary liver lesions and an unchanged primary tumor. The disease
remained stable for 18 months until the patient had to be hospitalized for high blood glucose levels.
Along with the diagnosis of insulin-dependent diabetes mellitus, new liver metastases were found. Five
years after the diagnosis, the patient is still alive and receives the fourth line of chemotherapy (5-FU and
leucovorin).

Discussion

The prognosis for patients with metastatic pancreatic cancer is extremely poor, with a
median survival time of 3–6 months [2]. The standard cytotoxic treatment is gemcitabine
[5]. However, the addition of other agents such as cisplatin, irinotecan, oxaliplatin,
taxanes and biologically targeted agents has shown higher response rates [7]. According to a recently published meta-analysis, gemcitabine in combination with capcitabine or oxaliplatin is associated with improved overall survival and overall response rates in locally advanced and metastatic pancreatic cancer patients, while the gemcitabine/cisplatin combination showed no survival benefit compared to the gemcitabine monotherapy [8].

For refractory pancreatic cancer, however, there is no consensus regarding the optimal treatment. Oettle et al. [9], when they evaluated FOLFOX as a second-line treatment in advanced pancreatic cancer, found that chemotherapy offers better overall survival to refractory patients as compared to best supportive care. According to the final results of the CONKO-003 trial, the addition of oxaliplatin to 5-FU and leucovorin improves overall survival and progression-free survival when compared to treatment with 5-FU and leucovorin alone [10]. Some studies have demonstrated the efficacy of gemcitabine/oxaliplatin combination chemotherapy as second-line treatment [11]. Combination of oxaliplatin and capcitabine after treatment failure with gemcitabine has shown some activity [6]. Paclitaxel as monotherapy has considerable efficacy and low toxicity in second-line treatment [12], as does FOLFIRI [13]. Bevacizumab and erlotinib combination showed poor results [14], as did the use of sunitinib as a single agent [15]. Overall, little progress has been made so far in the field of refractory pancreatic cancer treatment, and there is no evidence-based treatment recommended for these patients.

Cisplatin monotherapy is seldom considered in modern treatment of refractory pancreatic cancer, although it is a widely used chemotherapeutic drug and the first member of a class of platinum-containing anticancer drugs. The number of patients initially responding to this therapy is high; however, the majority of cancer patients eventually relapse with cisplatin-resistant disease. According to our possibilities and clinical experience, we introduced cisplatin administered by bi-weekly infusion as third-line chemotherapy in our patient. This resulted in a remarkable response, providing 18 months of disease stability and contributing to a 5-year survival in an initially unresectable patient with liver and lymph node metastases. Thus, although today surpassed by new exciting drugs and their combinations, cisplatin monotherapy should be considered in refractory pancreatic cancer patients with satisfactory serum creatinine levels. It represents a valuable option in these patients, especially when one is faced with non-medical limitations in form of means restriction.
References


